Awful. Horrendous. Really difficult. This is how a clinical trial transparency expert describes the task of identifying confidential business information in clinical reports made public under the transparency initiatives of Health Canada and the European Medicines Agency.
Both initiatives involve the proactive disclosure of clinical data that were used to support a marketing authorization application after a...







